Navigation Links
Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs

New study has suggested that therapeutics based on monoclonal antibodies (mAbs) are fare more likely to be commercially successful than their small molecule predecessors. According to a study completed by // consultancy Propagate Pharma, about half the mAbs launched so fare appear to be profitable. That means mAbs are recouping more in revenues than their estimated $1 billion to $1.8 billion cost of development and marketing. By comparison, the study estimates that only 30% of conventional small molecule drug launches ever recover their costs. Drug is likely to be profitable if peak revenues pass the $300 million mark. So far, of the 17 mAbs launched in the US, eight have achieved this benchmark. And of these, four have become blockbusters earning over a billion dollars a year.

Of 57 mAbs launched so far, 16 have become blockbusters, 14 have at least recouped their costs, and the other 27 are either question marks or failures. The high success rate of biotherapeutics is due to low levels of competition in the markets they address, says Jo Collett, author of the Propagate study. There are signs that the tail end of a biotherapeutics products life cycle might be more profitable than that of a small molecule drug. However, this high level of success may be difficult to sustain as competition increases, especially in the cancer market, says Propagate’s Collett. “It’s not going to be quite as easy as it was for the pioneers,” she prophesies.

There are more than 150 mAbs in development worldwide, over 100 of which are in phase 2 or phase 3 trials. Nearly 40% of these are in the oncology field; 18 are in development for breast cancer alone. Collett predicts that companies launching the next generation of mAb therapeutics will have to be more commercially acute with a better understanding of their products positioning that the pioneers of the field were. Although there is respectable data showing that obtaining regulatory approval tends to be easier for antibodies than for other drug classes, he warns it is too early to make firm predictions. “The mid and longer term future may look quite different in terms of competitive threats, so past performance is not necessarily a guide”.

Source: Nature Biotechnlogy.
'"/>




Related medicine news :

1. Understanding Chronic Infections May Help in Developing Therapeutic Vaccines
2. Therapeutic cloning by regenerating stem cells from heart muscles
3. Therapeutic Genes Transferred By Viral Vector Through T Cell Masking
4. Functional Differences In Estrogen Receptor Could Be A Therapeutic Target
5. Clinical-trials Show Increased Therapeutic Activity of Pycnogenol than Daflon
6. Safety of Cancer Therapeutic Viruses Enhanced
7. Researchers Enhance Safety and Effectiveness of Therapeutic Virus that Fights Cancer
8. Human Embryonic Stem Cells Could Be Later Used In Therapeutic Cloning
9. Contemporary Therapeutic Guidelines For HIV Patients
10. Potential New Therapeutic Target for Asthma, Allergies and Cancer
11. VBI Provides Potential Targets to Diabetes Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/16/2017)... ... August 16, 2017 , ... Melbourne’s reign as the world’s most liveable ... Unit’s (EIU) annual Liveability Index. , The Index surveys 140 of the world’s cities ... 2006, Melbourne has consistently come in the top three of the index. So what ...
(Date:8/16/2017)... ... August 16, 2017 , ... Connexion Point, a technology-enabled healthcare services company ... fourth consecutive year. With 197% revenue growth over the past three years, ... growing companies. , Previous honors include ranking 86th on the Inc. 500 ...
(Date:8/16/2017)... Rochester, Michigan (PRWEB) , ... August 16, 2017 ... ... treatment options to patients suffering from chronic pelvic pain. In addition to ... various pelvic pain disorders including endometriosis, menorrhagia (abnormal heavy bleeding during menstruation), uterine ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... an annual all-encompassing awards program which recognizes organizations that demonstrate the core values ... of comprehensive award categories. , “As a global company, we are expanding our ...
(Date:8/16/2017)... ... ... “Mom, God's Got This: Jamie's Story” is the creation of published author, Karen F. Norton, ... insatiable appetite for God’s Word. , “I froze between the half walls, shelves on my ... oatmeal. I have one to this day on proud display in my dining room hutch; ...
Breaking Medicine News(10 mins):
(Date:8/1/2017)... CerSci Therapeutics , a non-opioid drug development firm based ... notice from the National Institute on Drug Abuse (NIDA) ... has been awarded a Direct-to-Phase II Small Business Innovation ... an additional $1,000,000 to follow in 2018. These funds ... lead non-opioid drug candidate CT-044 to the Food and ...
(Date:7/28/2017)... 2017 EnvoyHealth, a Diplomat company, has partnered with ... CleverCap LITE, a technology designed to improve patient medication ... health technology solutions and services that help track and ... CleverCap LITE offers medication monitoring and control for ... Records date and time ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals Company, ... our clinical trial evaluating Altemia TM , an oral ... and Sickle Cell Disease (SCD). The SCOT Trial, is ... efficacy and safety of Altemia TM in pediatric ... under US IND 125274. ...
Breaking Medicine Technology: